Targeting HSP90 destabilization with ganoderic acid a as a novel therapeutic strategy for hepatoblastoma - PubMed
4 hours ago
- #HSP90
- #Hepatoblastoma
- #Ganoderic acid A
- Hepatoblastoma (HB) is the most prevalent primary liver malignancy in children with poor prognosis for high-risk or relapsed cases.
- Ganoderic acid A (GAA), derived from Ganoderma lucidum, shows antitumor activity but its role in HB was unexplored.
- GAA inhibits proliferation, migration, and invasion in HB cells, while inducing apoptosis and cellular senescence.
- In vivo studies show GAA reduces tumor burden in HB xenograft models.
- GAA interacts with HSP90, impairing its function and promoting degradation, with HSP90 overexpression attenuating GAA's effects.
- Molecular dynamics simulations confirm stable binding between GAA and HSP90.
- GAA is identified as a novel senescence-inducing agent in HB via HSP90 degradation, suggesting a new therapeutic strategy.